| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司自成立以来，高度重视创新能力的打造与提升，通过十余年持续增长的研发费用及人员投入，打造了肿瘤精准医疗所需的PCR、NGS、IHC、FISH等技术平台，构建了从靶向治疗到免疫治疗的全方位伴随诊断产品体系，拥有国际领先、完全自主知识产权的ADx-ARMS?、Super-ARMS?、ddCapture?、ADx-HANDLE?、ADx-GSS?等技术和算法专利，共同推动公司高质量发展。公司在研发上持续不断地投入和积累，也获得了国家和行业的认可，荣获“国家企业技术中心”、“博士后科研工作站”、“专精特新‘小巨人’企业”等资质，彰显公司研发实力。 公司下设两家独立第三方医学检验机构——厦门艾德医学检验实验室、上海厦维医学检验实验室，拥有卫健委颁发的《医疗机构执业许可证》（医学检验科；临床细胞分子遗传学专业/病理科），具备全线开展细胞病理、组织病理、分子病理临检服务的资质和能力。两家实验室拥有PCR、NGS、数字PCR（ddPCR）、FISH、Sanger、IHC等全套技术平台，通过美国CAP认证和ISO15189认证，按照CAP、CLIA检测实验室运行标准进行管理和质量控制，同时依托公司强大的科研力量，可根据不同项目选择最优的技术平台进行LDT产品设计与开发，满足药企、科研机构的多种需求，承接并出色完成了众多知名药企重要肿瘤药物的临床试验研究工作，获得合作伙伴的高度认可。厦门艾德医学检验实验室获国家发改委批准，成为“肿瘤基因检测技术临床应用中心”单位，为全国肿瘤精准基因检测技术的临床应用起到标杆示范作用。 公司拥有独立、完整的采购、生产、销售模式，并根据市场需求及自身发展情况，不断完善经营模式。 采购模式：公司实行集中采购管理制度，由采购部门统一负责原辅材料采购供应，保证公司生产经营工作的正常进行。公司特别注重研发、生产关键原材料的供应商管理工作，不存在关键原材料仅有一家进口供应商的情况。极端情况下，公司具备自产关键原材料的能力。 生产模式：公司主要产品为分子诊断试剂，生产步骤主要包括配液、分装、外包装、检验等，部分生产步骤已经实现自动化。公司制定了严格的《生产流程管理制度》，对生产过程运作的人员、物料、环境、设备以及生产工序进行有效控制，以提高生产效率、保证产品质量达标并符合监管部门规定的生产要求。公司重视安全生产，通过对生产流程各环节的严格控制确保全过程处于稳定的受控状态。 销售模式：公司所从事的肿瘤精准医疗分子诊断行业属于前沿热点领域，市场处于快速发展阶段，市场推广对于专业程度要求较高。在国内市场，公司采用“直销与经销相结合，直销为主、经销为辅”的销售模式，国内销售团队400余人，负责全国市场营销服务工作；在直销网络之外的市场，公司积极寻求与药企或经销商以产品代理的形式及旗下医学检验实验室以检测服务的形式进行覆盖。公司销售模式的选择符合产品特点和临床市场需求，也符合减少中间流通环节的医改政策导向。在国际市场，公司建立了覆盖全球60多个国家和地区的国际业务团队，积极寻求和当地经销商、终端、跨国药企的合作机会。 | ||||||||||||||||||||||||
| Main Business | 肿瘤精准医疗分子诊断产品的研发、生产及销售，并提供关的检测服务。 | ||||||||||||||||||||||||
| Legal Representative | 郑立谋 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | -- | ||||||||||||||||||||||||
| Solicitors | 上海市锦天城律师事务所 | ||||||||||||||||||||||||
| Auditors | 立信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0592-6806830 | ||||||||||||||||||||||||
| Fax No | 0592-6806203 | ||||||||||||||||||||||||
| Website | www.amoydx.com | ||||||||||||||||||||||||
| sid@amoydx.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 02/08/2017 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.660 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.150 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 4.273 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 7.243B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |